Expert Insights: Why Dietary Supplements Do Not Lower Cholesterol

For the first time, the 2026 ACC/AHA Dyslipidemia Guideline includes a formal recommendation against the use of dietary supplements for lipid lowering, a position supported by randomized controlled trial evidence and one carrying significant implications for patient counseling and shared decision-making in cardiovascular prevention.

Pamela B. Morris, MD, vice chair of the writing committee, and Ann Marie Navar, MD, PhD, address this topic with candor, acknowledging the appeal of supplement-based approaches while emphasizing wishful thinking cannot override clinical evidence.

Randomized trial data demonstrate the most commonly promoted dietary supplements, including omega-3 fatty acids in supplement formulations, vitamin D, vitamin E, vitamin C, and red yeast rice extract, fail to produce meaningful LDL cholesterol reduction or cardiovascular event reduction. The SPORT trial, comparing very low-dose rosuvastatin (5 mg) against multiple supplements including red yeast rice, found minimal to no benefit from the supplement arm in terms of LDL lowering.

Navar draws particular attention to the regulatory distinction between supplements and pharmaceuticals: the "supports heart health" labeling permitted on supplements carries no requirement for demonstrated disease prevention benefit. Red yeast rice extract, she explains, contains lovastatin as its active ingredient, but unlike a prescribed statin, it arrives without standardized dosing, pharmaceutical-grade manufacturing controls, or regulatory oversight. For patients seeking to lower LDL or reduce cardiovascular event risk, the guideline directs clinicians toward evidence-based pharmacotherapy.

This recommendation is expected to generate pushback from some patients, particularly those preferring "natural" approaches or harboring concerns about statin side effects. It reinforces the guideline's broader message: clinicians should ground these conversations in outcomes data, and the expanded pharmacologic toolkit now available, including non-statin options with robust cardiovascular outcomes evidence, leaves little clinical justification for relying on unproven supplement regimens.

Morris has no relevant disclosures to report. Navar reports disclosures with Amge, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly and Company, Esperion, Johnson & Johnson, Merck, Miga Health, NewAmsterdam Pharma, Novartis, Novo Nordisk, Sanofi, and Silence Therapeutics, among others.

References:

1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. Published online March 13, 2026. doi:10.1016/j.jacc.2025.11.016
2. American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology. American College of Cardiology. Published March 13, 2026. Accessed March 23, 2026. https://www.acc.org/About-ACC/Press-Releases/2026/03/13/18/01/ACCAHA-Issue-Updated-Guideline-for-Managing-Lipids-Cholesterol